A Phase I Clinical Trial in 18-60 Adults

Condition:   COVID-19 Intervention:   Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Sponsors:   CanSino Biologics Inc.;   Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China;   Jiangsu Province Centers for Disease Control and Prevention;   Hubei Provincial Center for Disease Control and Prevention;   Tongji Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials